At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 933 enrolled
Drug / intervention
Aclidinium Bromide / Formoterol Fumarate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 3 clinical trial evaluating Aclidinium Bromide / Formoterol Fumarate and Salmeterol / Fluticasone for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 933 participants across 126 sites in 14 countries.
Detailed Summary
The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustria, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartSep 2013
Primary CompletionAug 2014
TodayJul 2026
First PostedJul 25, 2013
Enrollment StartSep 1, 2013
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.9 years ago
Interventions
Aclidinium Bromide / Formoterol Fumaratedrug
Salmeterol / Fluticasonedrug